Accurate and quantitative detection of pre-eclampsia markers is crucial in reducing pregnancy mortality rates. This study introduces a novel approach utilizing a fluorescent biosensor by the immunosorbent atom transfer radical polymerization (immuno-ATRP) assay to detect the pre-eclampsia protein marker CD81. The critical step used in this sensor is the novel signal amplification strategy of fluorescein polymerization mediated by ferritin-enhanced controlled radical polymerization, which combines with a traditional enzyme-linked immunosorbent assay (ELISA) to further reduce the detection limit of the CD81 protein concentration. The fluorescence intensity was linear versus logarithmic CD81 protein concentration from 0.1 to 10,000 pg mL^–1, and the detection limit was 0.067 pg mL^–1. Surprisingly, in 30% normal human serum (NHS), the sensor can also detect target protein over 0.1–10,000 pg mL^–1, with 0.083 pg mL^–1 for the detection limit. Moreover, the proposed biosensor is designed to be cost-effective, making it accessible, particularly in resource-limited settings where expensive detection techniques may not be available. The affordability of this method enables widespread screening and monitoring of preeclampsia, ultimately benefiting many pregnant women by improving their healthcare outcomes. In short, developing of a low-cost and susceptible direct detection method for preeclampsia protein markers, such as CD81, through the use of the immuno-ATRP assay, has significant implications for reducing pregnancy mortality. This method holds promise for early detection, precise treatment, and improved management of preeclampsia, thereby contributing to better maternal and fetal health.

中文翻译：

---

通过免疫吸附原子转移自由基聚合测定对子痫生物标志物进行荧光传感


准确定量检测先兆子痫标志物对于降低妊娠死亡率至关重要。本研究介绍了一种利用荧光生物传感器通过免疫吸附原子转移自由基聚合 (immuno-ATRP) 测定来检测先兆子痫蛋白标记 CD81 的新方法。该传感器采用的关键步骤是铁蛋白增强的受控自由基聚合介导的荧光素聚合的新型信号放大策略，该策略与传统的酶联免疫吸附测定（ELISA）相结合，进一步降低了CD81蛋白浓度的检测限。荧光强度与对数 CD81 蛋白浓度在 0.1 至 10,000 pg mL ^–1 范围内呈线性关系，检测限为 0.067 pg mL ^–1 。令人惊讶的是，在 30% 正常人血清 (NHS) 中，该传感器还可以检测超过 0.1–10,000 pg mL ^–1 的目标蛋白，检测限为 0.083 pg mL ^–1 。此外，所提出的生物传感器被设计为具有成本效益，使其易于使用，特别是在可能无法使用昂贵的检测技术的资源有限的环境中。这种方法的经济性使得能够广泛筛查和监测先兆子痫，最终通过改善医疗保健结果使许多孕妇受益。简而言之，通过使用免疫 ATRP 测定开发一种低成本且敏感的先兆子痫蛋白标记物（例如 CD81）直接检测方法，对于降低妊娠死亡率具有重要意义。这种方法有望实现先兆子痫的早期检测、精确治疗和改善管理，从而有助于改善孕产妇和胎儿的健康。